Cargando…

Heterosubtypic cross‐protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration

BACKGROUND: Development of influenza vaccines capable of inducing broad protection against different virus subtypes is necessary given the ever‐changing viral genetic landscape. Previously, we showed that vaccination with whole inactivated virus (WIV) induces heterosubtypic protection against lethal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Budimir, Natalija, de Haan, Aalzen, Meijerhof, Tjarko, Gostick, Emma, Price, David A., Huckriede, Anke, Wilschut, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2013
Materias:	Part 3
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112805/ https://www.ncbi.nlm.nih.gov/pubmed/24102979 http://dx.doi.org/10.1111/irv.12142

Ejemplares similares

Induction of Heterosubtypic Cross-Protection against Influenza by a Whole Inactivated Virus Vaccine: The Role of Viral Membrane Fusion Activity
por: Budimir, Natalija, et al.
Publicado: (2012)

A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats
por: Kamphuis, Tobias, et al.
Publicado: (2013)

Critical Role of TLR7 Signaling in the Priming of Cross-Protective Cytotoxic T Lymphocyte Responses by a Whole Inactivated Influenza Virus Vaccine
por: Budimir, Natalija, et al.
Publicado: (2013)

Evaluation of an Intranasal Virosomal Vaccine against Respiratory Syncytial Virus in Mice: Effect of TLR2 and NOD2 Ligands on Induction of Systemic and Mucosal Immune Responses
por: Shafique, Muhammad, et al.
Publicado: (2013)

Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice
por: Kamphuis, Tobias, et al.
Publicado: (2012)

Inactivated influenza virus vaccine is efficient and reduces IL‐4 and IL‐6 in allergic asthma mice
por: Jian, You‐Ru, et al.
Publicado: (2013)

Superior Immunogenicity of Inactivated Whole Virus H5N1 Influenza Vaccine is Primarily Controlled by Toll-like Receptor Signalling
por: Geeraedts, Felix, et al.
Publicado: (2008)

Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization
por: Bhide, Yoshita, et al.
Publicado: (2019)

Seasonal influenza vaccine effectiveness among children, 2010–2012
por: Fu, Chuanxi, et al.
Publicado: (2013)

The genetic match between vaccine strains and circulating seasonal influenza A viruses in Vietnam, 2001–2009
por: Vuong, Cuong D., et al.
Publicado: (2012)

A study of Chitosan and c‐di‐GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine
por: Svindland, Signe C., et al.
Publicado: (2012)

A prospective study of chemotherapy immunologic effects and predictors of humoral influenza vaccine responses in a pediatric oncology cohort
por: Kersun, Leslie S., et al.
Publicado: (2012)

Characterization of humoral immune responses and degree of protection induced by influenza vaccine in cotton rats: Effects of low vaccine dose and single vs booster vaccination
por: Bhide, Yoshita, et al.
Publicado: (2020)

Effect of passive immunization on immunogenicity and protective efficacy of vaccination against a Mexican low‐pathogenic avian H5N2 influenza virus
por: Forrest, Heather L., et al.
Publicado: (2013)

Effectiveness of seasonal influenza vaccine in preventing medically attended influenza infection in England and Wales during the 2010/2011 season: a primary care‐based cohort study
por: Kafatos, George, et al.
Publicado: (2013)

Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF‐10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses
por: Kimoto, Takashi, et al.
Publicado: (2013)

Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow‐fill‐seal device in adults: a randomized, active‐controlled study
por: Sheldon, Eric A., et al.
Publicado: (2012)

Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines
por: Dong, Wei, et al.
Publicado: (2018)

Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs
por: Geeraedts, Felix, et al.
Publicado: (2008)

Strategic communication as planned behavior for science and risk communication: A theory‐based approach to studying communicator choice
por: Besley, John C., et al.
Publicado: (2022)

Are you prepared for the next storm? Developing social norms messages to motivate community members to perform disaster risk mitigation behaviors
por: Lim, JungKyu Rhys, et al.
Publicado: (2022)

Adjuvantation of Pulmonary-Administered Influenza Vaccine with GPI-0100 Primarily Stimulates Antibody Production and Memory B Cell Proliferation
por: Patil, Harshad P., et al.
Publicado: (2017)

Innate Responses Induced by Whole Inactivated Virus or Subunit Influenza Vaccines in Cultured Dendritic Cells Correlate with Immune Responses In Vivo
por: Stoel, Maaike, et al.
Publicado: (2015)

Preservation of the Immunogenicity of Dry-powder Influenza H5N1 Whole Inactivated Virus Vaccine at Elevated Storage Temperatures
por: Geeraedts, Felix, et al.
Publicado: (2010)

Vaccines - safety in pregnancy
por: Arora, Mala, et al.
Publicado: (2021)

Safety and tolerability of a 2009 trivalent inactivated split‐virion influenza vaccine in infants, children and adolescents
por: Lambert, Stephen B., et al.
Publicado: (2013)

Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production
por: Herrera-Rodriguez, José, et al.
Publicado: (2019)

Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication
por: Draghiciu, Oana, et al.
Publicado: (2015)

Advances in the development of universal influenza vaccines
por: Gilbert, Sarah C.
Publicado: (2012)

Enhancement of the Immunogenicity and Protective Efficacy of a Mucosal Influenza Subunit Vaccine by the Saponin Adjuvant GPI-0100
por: Liu, Heng, et al.
Publicado: (2012)

Guidelines for vaccinations of a normal child in India
Publicado: (2016)

Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20–64 years, 2007–2011
por: Kelly, Heath A., et al.
Publicado: (2012)

Evaluation of Mucosal and Systemic Immune Responses Elicited by GPI-0100- Adjuvanted Influenza Vaccine Delivered by Different Immunization Strategies
por: Liu, Heng, et al.
Publicado: (2013)

Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines
por: Sridhar, Saranya
Publicado: (2016)

Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response
por: Carascal, Mark B., et al.
Publicado: (2022)

The potential economic value of a ‘universal’ (multi‐year) influenza vaccine
por: Lee, Bruce Y., et al.
Publicado: (2011)

A plant‐based system for rapid production of influenza vaccine antigens
por: Shoji, Yoko, et al.
Publicado: (2011)

Comparative safety, immunogenicity, and efficacy of several anti‐H5N1 influenza experimental vaccines in a mouse and chicken models (Testing of killed and live H5 vaccine)
por: Gambaryan, Alexandra S., et al.
Publicado: (2011)

Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant
por: Luo, Jian, et al.
Publicado: (2019)

Bacterium-Like Particles for Efficient Immune Stimulation of Existing Vaccines and New Subunit Vaccines in Mucosal Applications
por: Van Braeckel-Budimir, Natalija, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ektids7kgigo56rml3vrsl1jct